We describe a system that permits conditional mobilization of a Sleeping Beauty (SB) transposase allele by Cre recombinase to induce cancer specifically in a tissue of interest. To demonstrate its potential for developing tissue-specific models of cancer in mice, we limit SB transposition to the liver by placing Cre expression under the control of an albumin enhancer/promoter sequence and screen for hepatocellular carcinoma (HCC)-associated genes. From 8,060 nonredundant insertions cloned from 68 tumor nodules and comparative analysis with data from human HCC samples, we identify 19 loci strongly implicated in causing HCC. These encode genes, such as EGFR and MET, previously associated with HCC and others, such as UBE2H, that are potential new targets for treating this neoplasm. Our system, which could be modified to drive transposon-based insertional mutagenesis wherever tissue-specific Cre expression is possible, promises to enhance understanding of cancer genomes and identify new targets for therapeutic development.
Transposon-tagged mutagenesis has proven invaluable for functional genomics in organisms such as Drosophila melanogaster 1,2 , but similar progress in mammalian systems has been retarded by the long delay in identifying transposons, such as Sleeping Beauty (SB), which are active in mouse cells 3 . Although the low frequency of SB transposition in the mouse germ line [4] [5] [6] had suggested that the frequency of SB mobilization in somatic tissues was too low to induce cancer, SB transposons have been mobilized in somatic cells at frequencies high enough to induce cancer in wild-type mice 7 and accelerate the formation of tumors in p19 Arf -deficient mice 8 . Nonetheless, it was not possible to model specific tumor types when expressing SB from a ubiquitous promoter. Whereas SB transposition in p19 Arf -deficient mice accelerated the formation of tumors normally observed in these mice 8 , in wild-type mice, it resulted in the formation of aggressive hematopoietic tumors that killed the animals by 4 months of age 7 . Mice did not live long enough to develop other types of tumors such as solid tumors.
To address this need, we sought to develop a conditional SB transposition system to screen for genes associated with different types of cancer. For this, we first integrated the SB transposase allele SB11 carrying a loxP-flanked ('floxed')-stop (lsl) cassette into the mouse Rosa26 locus, which encodes a ubiquitously expressed nonessential gene 9 . Genes inserted into the Rosa26 locus are expressed in most tissues and not subject to epigenetic silencing normally observed with transgenes 9 . Expression of the transposase knock-in (Rosa26-lsl-SB11), which is normally blocked owing to the presence of the floxed-stop cassette, can be reactivated in any target tissue using a tissue-specific Cre recombinase to drive the transposition of the T2/ onc mutagenic transposon 7, 8 . The T2/onc vector contains sequences that can both cause misexpression of an oncogene and inactivate a tumor suppressor gene ( Supplementary Fig. 1a online) .
HCC is the third leading cause of cancer-related deaths globally 10 , with potential curative treatment available for o30% of patients at the time of diagnosis 11 . HCC is prevalent worldwide, with differences in rates of its incidence reflecting regional diversity mostly related to the geographic distribution of viral hepatitis 11 . A greater prevalence in males, relative to females, has been explained by preliminary molecular data 12 . Mutations in the TP53 gene are commonly found in HCC 13, 14 . The presence of many unexplained recurrent chromosomal abnormalities and the identification of mRNA expression-based subsets of HCC suggest the presence of unidentified genetic drivers of this disease 15 .
We used a hepatocyte-specific albumin-Cre (Alb-Cre) transgene to activate transposase expression in mice, specifically in the liver 16 . As mutations in TP53 are the most frequently described mutations in human HCC, we included a conditional dominant negative Trp53 transgene 17 in a second construct, named p53-lsl-R270H (Supplementary Fig. 1a ). We bred triple transgenic (Rosa26-lsl-SB11; T2/onc; AlbCre) and quadruple transgenic (Rosa26-lsl-SB11; T2/onc; Alb-Cre; p53-lsl-R270H) mice and monitored the onset of liver tumorigenesis in both sets of lines ( Supplementary Fig. 1b ). When combined with high-throughput sequencing, our conditional forward genetics screen identified 19 genes potentially associated with oncogenesis in the liver and prioritized epidermal growth factor receptor (Egfr) and ubiquitinconjugating enzyme E2H (Ube2h) for experimental validation. Egfr was the most frequently mutated gene in our screen and was especially prevalent as a truncated form lacking the C-terminal half of the gene. Moreover, initial human comparative studies suggest a nonsignificant trend to higher tumor recurrence and poorer survival rates associated with higher expression levels of UBE2H. This information enhances insight into the genetic mechanisms associated with HCC and may facilitate development of more effective therapies.
RESULTS

Hepatocyte-specific transposition and tumorigenesis
To demonstrate that the conditional transposase knock-in is activated exclusively in the liver, we used an anti-SB transposase (SB) antibody for immunohistochemical analyses of mice carrying both Alb-Cre and Rosa26-lsl-SB11 transgenes (Fig. 1a) . To confirm that transposition is occurring in the livers of experimental transgenic animals, we used excision PCR 8 to demonstrate amplicon excision ( Supplementary  Fig. 2a online) when experimental and control animals from both sexes were initially euthanized B100 d after birth. No visible lesions were seen in any organs at this stage (data not shown).
Preneoplastic liver nodules were first detected in male triple (nonpredisposed genetic background) and quadruple (predisposed to HCC by expression of a dominant-negative Trp53 allele) transgenic animals B160 d after birth. Nodules in the quadruple transgenic animals were larger and more numerous than those from triple transgenic animals ( Supplementary Fig. 2b ). Double and triple transgenic mice carrying all possible combinations of the four transgenes were also generated to provide control cohorts. Throughout our studies, we saw no evidence of tumorigenesis in control male littermates euthanized at a similar age (data not shown).
Of six quadruple transgenic male experimental animals euthanized between 101 and 223 d after birth, four (67%) had livers with macroscopic preneoplastic nodules (Fig. 1b) ; a total of 67 nodules were isolated (Supplementary Table 1 online) . In contrast, we found evidence of neoplasms in only three (43%) of the seven triple transgenic male animals euthanized between 105 and 289 d after birth and isolated 36 preneoplastic nodules from these animals (Supplementary Table 1) . Excision PCR assays confirmed . Middle (low magnification) and right (high magnification of boxed area from middle panel) panels show the tumor histology of several adenomas using hematoxylin-eosin (HE) staining. These adenomas often compressed surrounding parenchyma. Cells within the preneoplastic foci and adenomas were frequently vacuolated, containing distinct lipid vacuoles or clear cytoplasm (arrows). Nuclei were in the same size or smaller than those in the normal hepatic parenchyma, and occasionally contained mitotic figures indicative of cell division. Adenomas were frequently bordered by hepatocytes with markedly enlarged nuclei that were occasionally karyomegalic. T, tumor nodule; P, parenchymal liver cells; scale bars for middle and right panels, 500 mm and 100 mm, respectively. ) show advanced HCC in the liver and its metastasis into the lung. A partial HCC section reveals irregular trabeculae of neoplastic, diffusely necrotic hepatocytes (black arrows) that are multifocally vacuolated. Trabeculae are separated by dilated sinusoids containing variable amounts of fibrin. The lung contains multiple variably sized metastatic nodules of HCC (black arrows) that markedly compress the pulmonary parenchyma. Pulmonary alveoli are filled with many foamy macrophages. Scale bars in middle and right panels, 100 mm.
transposition in the livers of experimental animals that did not produce tumors ( Supplementary Fig. 2a) .
Detailed histopathological analyses revealed that the livers of triple and quadruple transgenic mice euthanized B150 d after birth frequently contained preneoplastic foci of cellular alteration that represents the earliest visible stage of neoplastic formation, with a few adenomas (Fig. 1b) . The liver of a 330-d-old triple transgenic male mouse had multiple large well-vascularized tumors with microscopic features of hepatic adenoma (Fig. 1c) . Two older triple transgenic male mice (440 and 460 d old) and a 432-d-old quadruple transgenic male mouse displayed lung metastases as well as livers with histopathological features of HCC ( Fig. 1d and Supplementary Table 1 ). Immunohistochemical analysis of preneoplastic nodules from all triple and quadruple transgenic livers stained positive for SB, albumin and for the cellular proliferative marker, Ki67 (Fig. 2a) . This indicates that these nodules result from transposition events originated from hepatocytes and have increased rates of proliferation. The lung metastases also stained positive for SB, albumin and Ki67 using immunohistochemistry, indicating that they were derived from the HCC (Fig. 2b) .
Although RT-PCR revealed that the majority of preneoplastic nodules expressed alpha-fetoprotein (Afp), a biomarker for human HCC (Fig. 3) , only a small subset of nodules expressed enough Afp to enable detection by immunohistochemistry (data not shown). RT-PCR also demonstrated the expression of secreted phosphoprotein 1 (Spp1)-a gene associated with HCC metastasis 18 -in all preneoplastic nodules (Fig. 3d) . Semi-quantitative RT-PCR demonstrated upregulation of Ssp1 and Afp expression as liver tumorigenesis progressed from adenoma to HCC (Supplementary Fig. 2c ).
Immunohistochemical analyses for b-catenin levels demonstrated increasing levels of expression as tumorigenesis progressed from preneoplastic nodules to hepatic adenoma to HCC ( Supplementary  Fig. 3 online) . Mutations in the gene encoding b-catenin and its elevated expression are also observed in human HCC 19 . Notably, triple (n ¼ 4) and quadruple (n ¼ 4) transgenic female experimental animals (euthanized 178-342 d after birth and 178-344 d after birth, respectively) did not have any visible liver lesions (Supplementary Table 1 ). However, two female triple transgenic animals (512 and 575 d old) and one quadruple transgenic animal (432 d old) presented livers with small preneoplastic nodules (Supplementary Table 1 ). The low frequency and prolonged latency of liver nodules in female experimental animals mirrors the strong gender bias in the incidence of HCC tumor seen in humans. Moreover, immunohistochemistry revealed increased expression of Afp and the proliferative marker Ki67 in nontumorigenic liver sections from female mice ( Supplementary  Fig. 4a online) . Therefore, our conditional SB liver tumor model is useful in elucidating genetic mechanisms for HCC tumorigenesis, including lesions ranging from early hepatic adenomas to fully developed HCC, including metastatic HCC. Supplementary Figure 1c online provides a flow chart for SB somatic cell mutagenesis and barcode-assisted integration site amplification. Briefly, T2/onc integration sites from 68 preneoplastic nodules (3 from triple and 65 from quadruple transgenic animals) were cloned and sequenced using barcoded primers and linker-mediated PCR. Subsequent pyrosequencing 20 enables tens of thousands of T2/onc integration sites from a mixture of tumors to be characterized in a single sequencing run (Supplementary Methods online). Pyrosequencing of linker-mediated PCR products from these tumors generated over 140,000 individual sequences. Sequences containing o16 nucleotides of genomic sequence were eliminated, leaving B106,000 sequences. From these, 85,652 sequences were uniquely mapped at 95% identity to the mouse genome. As SB has a tendency to 'hop' primarily within the vicinity of the original site of integration 6 , we excluded insertions that mapped to the transposon donor chromosome (chromosome 15). Further elimination of insertions that did not map to the canonical TA insertion site required for SB integration [21] [22] [23] left a total of 68,782 sequences. We then combined all insertions that mapped to the same TA dinucleotide and originated from the same neoplastic nodule, leaving a final tally of the 8,060 nonredundant insertions.
Sequencing identifies common insertion sites in tumors
We next looked for regions in the genome that had more SB insertions than predicted by random chance. These so-called common insertions sites (CISs) are most likely to harbor disease-related genes. Based on Monte Carlo criteria for statistical significance (Supplementary Methods), we defined CISs as regions in the genome with six insertions located within 130 kb of each other, five insertions within 65 kb or four insertions within 20 kb. In total, 30 CISs were identified according to these criteria. Of these CISs, 11 appear to represent background events resulting from false priming at a specific site. This is because the T2/onc insertions either all begin at the same nucleotide, occur in loci with no annotated genes or are present among CISs defined by control insertion-site-mapping experiments using 3-weekold transgenic-mouse tail DNA carrying both the T2/onc and Rosa26-SB11 transgenes (Supplementary Methods). The final list of CISs associated with mouse HCC is shown in Table 1 and the 8,060
nonredundant sites of insertion are provided in Supplementary Data online. Notably, substantial overlap with this CIS list was seen in another set of liver tumors induced by a villin-Cre transgene (data not shown), further attesting to the significance of these genes for HCC. Villin is expressed in the microvilli of brush border epithelium lining of the gut and renal tubes in vertebrates. Importantly, the specific insertion sites associated with individual preneoplastic nodules during early tumorigenesis differed for each nodule, indicating that each nodule is a unique clone. In general, each preneoplasic nodule was characterized by a unique set of T2/onc insertions. Certain genes, such as Egfr, were reproducibly mutated by insertion mutations in nodules from the same mouse. However, these insertions are not in identical Except for two insertion sites (asterisks) missed by pyrosequencing, all amplicons corresponded with the pyrosequencing data. MW, 100-bp molecular standard; B6, C57BL/6 tail genomic DNA; H 2 O, double-distilled water (negative control). (d) RT-PCR analyses of tumor nodules. All neoplastic nodules were positive for SB transposase (SB) and albumin (Alb) transcripts, indicating transposition and that nodules were derived from hepatocytes, respectively. Most tumor nodules were positive for alpha-fetoprotein (Afp) transcripts, a clinical marker for HCC, and secreted phosphoprotein 1 (Ssp1), which is overexpressed in various cancers including HCC. Nodules taken from a 330-d-old triple transgenic male mouse with advanced tumors (shown in Fig. 1c) were strongly positive for Afp and Ssp1. All tumor nodules tested were positive for endogenous Egfr and for truncated-Egfr transcripts. NRAS liver tumor, HCC control taken from a tumorigenic liver overexpressing NRAS G12V oncogene 25 ; SB normal liver, normal liver taken from a SB-expressing mouse; beta-actin (Actb), control to show equal loading of mRNA used for RT-PCR. RT-negative controls were also performed for each sample and no visible bands were seen for any of the markers tested (data not shown TA dinucleotides, with a few exceptions. We therefore conclude that each preneoplastic nodule was derived from an independent event resulting from random transposon insertional mutagenesis events. In some cases, identical Egfr gene insertions did occur in separate nodules, but as all other insertions were different in those samples, we concluded that the identical TA dinculeotide insertions into Egfr had occurred by chance owing to the strong selective pressure for insertions in intron 24 (see below). We previously observed T2/onc insertions into identical TA dinucleotides in Braf and Notch1 in independent tumors in situations of strong positive selection for insertion into a specific part of an oncogene 7, 8 . In contrast, our lung metastasis analysis, described below, demonstrates that clonal relationships can be detected between primary tumors and metastatic derivatives because identical T2/onc insertions occur in individual metastasis samples and a primary liver HCC tumor taken from the same mouse.
Pathway analysis of select CIS genes
Ingenuity Pathways Analysis (IPA) is a software application that enables network and functional analyses of gene sets of interest based on a repository of molecular interactions, regulatory events and gene-to-phenotype associations culled from the life sciences literature. The application can determine cellular and disease phenotypes most significant to a set of genes and can build molecular networks based on literature findings and pathways. Therefore, we used IPA to obtain a better understanding of the possible pathways and interactions between CIS genes. Of the 17 CIS genes analyzed, the three most significant signaling or disease functional annotations are post-translational modification (P ¼ 4.61E-09), cancer (P ¼ 8.09E-06) and tumor morphology (P ¼ 8.09E-06) (Supplementary Table 2 online). The CIS list includes homologs of several human genes that have been implicated in tumor formation and apoptosis of tumor cell lines: EGFR, HIF1A, MAP2K4, MET, PAK4, VRK2, TRPM7 and TAOK3. IPA identified two network pathways overrepresented by human homologs of CIS genes. The first network includes two transcription factors (NFIB and HIF1A) and the second pathway involves genes that interact with TNF. The combined pathways from IPA are summarized in Figure 3a .
Frequent transposon insertions occur in Egfr
Transposon insertions in Egfr were detected in 85% (n ¼ 58) of preneoplastic liver nodules isolated from experimental animals. These transposon insertions were most frequently detected in intron 24 of Egfr ( Table 1 and Fig. 3b ) and in the antisense orientation, suggesting truncation of the gene product. Three-primer PCR genotyping using endogenous Egfr and transposon primers performed with genomic DNA isolated from individual tumor nodules confirmed the presence of transposon vectors in this locus (Fig. 3c) . RT-PCR also confirmed the presence of the predicted truncated Egfr transcript in these preneoplastic nodules (Fig. 3d) .
As Egfr insertions were also identified in preneoplastic nodules taken from a triple transgenic mouse, Egfr mutations also appear to contribute to tumorigenesis in a nonpredisposed genetic background. The insertions in this animal are predicted to result in a truncated Egfr protein (about 984 amino acids) containing the majority of the kinase domain but lacking the C-terminal domain. Indeed, this truncated Egfr was detected by western blot analysis in the liver tumors of older experimental triple transgenic male mice (Supplementary Fig. 4b ).
Lung metastases derived from HCC Analysis of genomic DNA taken from metastases of two triple transgenic male mice also demonstrated transposon insertion in intron 24 of Egfr, indicating that they were derived from the HCCs (Fig. 3e) . Thirty-two additional lung metastatic nodules were isolated from a 432-d-old quadruple transgenic male. Insertion sites from these metastatic nodules were compared to three individual HCC nodules taken from the same animal to identify a clonal relationship between primary liver tumors and metastases, and between metastases. One of the liver HCCs (HCC3) seemed to share a common ancestor with a second HCC (HCC2) as both have identical Egfr gene insertions, which are distinct from the Egfr insertion in HCC1 
Chr, chromosome; Range, chromosomal position of transposon insertions; n, frequency of transposon insertions; y, genes that did not have any transposon insertions from liver tumors generated with the villin-Cre transgenic mice used in the gastrointestinal cancer study (data not shown). Nodules, number of preneoplastic nodules from which the CIS was determined; Mouse, number of mice from which the nodules were isolated. Position based on the Ensembl NCBI m37 April 2007 mouse assembly.
( Fig. 4a) . Most of the metastases share four additional insertions with HCC2, indicating that the metastases share a common ancestor with HCC2. Three additional insertion mutations were found in most of the metastases (Fig. 4a) . From the phylogenetic tree generated from the insertion sites ( Fig. 4b and Supplementary Methods), primary liver tumor HCC2 and all lung metastases have the closest common ancestor, suggesting that the lung metastases are actually derived from liver tumor HCC2. These preliminary data suggest that SB-induced tumorigenesis allows one to derive clonal relationships between primary and metastatic derivatives, and to discover metastases-specific insertion mutations that may drive this biological process.
Comparison with human hepatocellular carcinoma samples
Representative oligonucleotide microarray analysis (ROMA) of 100 human HCCs showed that increases or decreases in copy numbers of 17 human homologs of our CIS genes have been associated with human HCC (Supplementary Table 3 online). We predict the effects of transposon insertions on CIS gene expression in Supplementary  Table 3 and Supplementary Methods. Genes with distinct copy number gains identified in human HCC samples (n ¼ 100), homologs of which are also disrupted in our mouse model, include EGFR, SLC25A13, MET and UBE2H. Genes with distinct copy number losses in human HCC samples, homologs of which were also identified as mouse CIS genes in our analysis, include MARCH1, PSD3, MAP2K4 and NFIB. We also analyzed another cohort of 132 human samples spanning the whole spectrum of human hepatocarcinogenesis: normal liver (n ¼ 10), cirrhotic liver (n ¼ 13), low-grade dysplastic nodules (n ¼ 10), high-grade dysplastic nodules (n ¼ 8) and HCC (n ¼ 91). Fifteen of the CIS genes were analyzed by combined single nucleotide polymorphism (SNP) and gene expression arrays. The most appealing candidates for clinical correlations were selected based on recurrent gene copy number changes, and correlated gene expression changes were compared with control samples (Supplementary Methods). Of the 15 genes, only three-MAP2K4, QKI and UBE2H-satisfy these criteria. MAP2K4 and QKI have losses of DNA copy numbers with reduced mRNA levels, whereas UBE2H has DNA copy number gains with a substantial increase in mRNA levels ( Supplementary Fig. 5a online) . Associations between MAP2K4, QKI and UBE2H expression and clinicopathological variables were analyzed in 82 hepatitis C-related HCC patients treated with liver resection (Supplementary Methods). Although, owing to the small sample population, these genes did not display a significant difference in outcome measured by tumor recurrence or survival, high expression levels of UBE2H displayed a nonsignificant trend toward lower survival rates (P ¼ 0.09) compared with low expression levels ( Supplementary Fig. 5c ). Studies involving the tyrosine kinase receptors EGFR and MET, both located on chromosome 7, recently showed that copy number gains of this chromosome are frequently associated with HCC and define a molecular class of HCC patients 24 ( Supplementary Fig. 5b ).
Functional validation of two CIS genes
As UBE2H seemed a strong candidate HCC oncogene, we used a cell proliferation assay to test its oncogenic potential. AML12 cells (adult mouse hepatocyte cell line, transgenic for human TGFA) stably transfected with a Ube2h expression vector have a higher proliferative rate than normal untransfected cells or AML12 cells transfected with an empty vector ( Supplementary Fig. 6 online) .
We used the Fah-deficient mouse model 25 to test whether the truncated form of EGFR could contribute to neoplastic growth in vivo. In this assay, a test transgene is codelivered with an Fah expression vector to allow selective repopulation of genetically transformed hepatocytes in vivo under conditions that would normally kill hepatocytes. Two vectors were generated: one (pT2/FAHIL) coexpresses Fah and firefly luciferase, whereas the other (pT2/PGKTruncated EGFR) expresses a truncated form of EGFR (exon 1 to exon 24) only (Fig. 5a) . We used tail-vein hydrodynamic injection 26 to administer the vectors to Fah-deficient mice that express the SB11 transposase knocked into the Rosa26 locus (Fah/SB11 mice). Upon withdrawal of NTBC (nitisinone, Orfadin), the mice underwent liver repopulation, as evidenced by stable weight gain and increasing luciferase expression (Fig. 5b) . When a mouse injected with both pT2/FAHIL and pT2/PGK-Truncated EGFR was euthanized 43 d after injection, several patches of hyperplastic nodules were visible in the liver (Fig. 5c) . RT-PCR revealed that these nodules express Fah and the truncated form of EGFR (Fig. 5d) . Although immunohistochemistry confirmed the inability to detect EGFR in normal Fah-deficient liver (Fig. 5e) , it also confirmed that induced hyperplastic liver nodules co-express Fah and EGFR 
Figure 4 SB-induced tumorigenesis reveals clonal relationships between primary and metastatic derivatives. (a) The clonal relationship between lung metastases and HCC samples. The heat-map was generated by mapping insertion sites from 32 lung metastases nodules and 3 HCC nodules taken from the same mouse (ATRP M232). Importantly, three additional insertion mutations were common in most of the metastases, indicating genes potentially involved in metastasis. Red, insertion detected at the indicated locus; black, no insertion detected at the indicated locus.
(b) Phylogenic tree generated from the insertion sites of the lung metastases and HCCs.
( Fig. 5f,g ). Notably, adjacent liver tissue, which appeared healthy, was negative for both transcripts (Fig. 5d) .
DISCUSSION
The recent development of target-based therapeutics for treating cancer has sparked a worldwide effort to identify all of the genes and signaling pathways that cause it. But despite the potential of transposon-based insertional mutagenesis for identifying cancer genes, it has been impossible to control transposition in a manner that allows different types of cancer to be modeled. We used a conditional SB allele and a hepatocyte-specific Cre recombinase to screen for HCCassociated genes in mice. As expected, quadruple transgenic mice displayed more numerous and larger tumor nodules than triple transgenic animals, as a result of the Trp53 mutant background, which predisposes animals to cancer. Our conditional SB liver-tumor model is useful in elucidating genetic mechanisms for all stages of HCC tumorigenesis-from early hepatic adenoma to fully developed HCC, including metastasis. Pyrosequencing technology facilitates the use of transposons for cancer gene identification by enabling amplification and sequencing of tens of thousands of SB insertion sites from a mixture of tumors in a single sequencing run. From 8,060 nonredundant insertions subsequently cloned from 68 tumor nodules, we identify 19 loci that seem strongly implicated in HCC. Our list of genes with multiple examples of CISs includes several homologs of human genes (e.g., EGFR, HIF1A, MAP2K4, MET, PAK4, VRK2, TRPM7 and TAOK3) that have been implicated in tumor formation and apoptosis of tumor cell lines. IPA identified two network pathways overrepresented by these homologs of CIS genes. The first network includes two transcription factors, NFIB and HIF1A, which are capable of transducing EGFR-initiated phosphorylation-signaling cascades. HIF1A has also been suggested to play a role in tumor vascularization 27 . The second pathway involves genes that interact with TNF. TNF can induce tyrosine phosphorylation and internalization of EGFR, playing a critical role in NF-kB activation 28 . NF-kB, in turn, plays an important role in regulating apoptosis during liver tumorigenesis 29 .
Transposon insertions in mouse Egfr that cause truncations in the C-terminal half of the gene product were common in SB-induced liver tumors. Deletions of the C-terminal domain of human EGFR (966-1006) have been shown to increase both autokinase activity and transforming ability in vitro and in vivo 30 . Internal deletions in the C terminus of EGFR have also been detected in naturally occurring EGFR mutants displaying tumorigenic properties [30] [31] [32] , probably resulting in constitutively active forms of the protein owing to the destabilization of the inactive EGFR monomeric complex 33 . It has been suggested that truncated Egfr can form a heterodimer with Erbb2 and transphosphorylate the tyrosine sites 34 . Tyrosine-phosphorylated Erbb2 could then lead to the activation of other signaling pathways by different mechanisms and may play a role in HCC tumorigenesis 35 . Besides HCC, EGFR overexpression has also been associated with human breast and gut cancers [36] [37] [38] [39] . EGFR is overexpressed in 15-40% of human HCCs and EGF signaling is activated in B50% of human HCCs 39, 40 . Although extra copies of EGFR were seen in 17 out of 38 (45%) HCC tumors, increased expression did not correlate with the increase in EGFR copy number 36 . Recent findings suggest that EGF signaling could even be related to HCC development based on significant differences in EGF genotype prevalence according to the risk of developing HCC 41 . In addition, use of erlotinib (Tarceva) to specifically target EGFR has shown interesting preliminary results in phase 2 clinical trials in human HCC 15, 42 .
The genes EGFR, SLC25A13, MET and UBE2H identified using CISs from our mouse model all showed distinct increases in copy number in human HCC samples. EGFR and MET are known proto-oncogenes, whereas SLC25A13 and UBE2H may have novel oncogenic activities in HCC. MET encodes the tyrosine kinase receptor for HGF and is overexpressed in HCC 43 . Although our algorithm predicted a Met gene disruption in our SB-induced tumors (Supplementary Table 3) , we suspect that these insertions actually activate the oncogenic activity of Met; five of six insertions could produce a kinase domaincontaining truncated protein or activate the gene by enhancer insertion. It is also possible that loss of function of Met contributes to tumor development as Met knockout mice are more prone to developing liver tumors 44 . Genes with distinct copy number losses in human HCC samples whose homologs were also identified as CIS genes by our mouse model, include MARCH1, PSD3, MAP2K4 and NFIB. MAP2K4 has been identified as a putative tumor-suppressor gene in human solid tumors of breast, prostate and pancreas, and may have a similar function in the liver [45] [46] [47] . Although PSD3 and MARCH1 have not been shown to be involved in cancer, based on data presented here, they may have tumor-suppressor activity in HCC. Interestingly, the transcription factor NFIB is known to be upregulated in hepatitisinduced HCC 48 . Another interesting finding is that a large number of the CIS genes have human homologs that map to chromosome 7, which has copy number amplifications in 415% of human HCCs 49, 50 . Moreover, when another cohort of 132 human samples spanning the whole spectrum of human hepatocarcinogenesis was compared with 15 human homologs of the CIS genes by combined SNP and gene expression arrays, preliminary results indicated a nonsignificant trend to higher tumor recurrence and poorer survival rates associated with higher expression levels of UBE2H. Our validation experiments and human comparative studies suggest a role for UBE2H in liver tumorigenesis. Furthermore, validation experiments confirmed the contribution of truncated EFGR to neoplastic growth in vivo.
A molecular classification of HCC based on gene copy number alteration and expression profiling was recently proposed 24 . The five classes, based on hierarchical clustering of gene expression data, are b-catenin, proliferation-and interferon-related neoplasms, a novel class of neoplasm defined by polysomy of chromosome 7 and an unannotated category. Although we did not recover recurrent insertions in Ctnnb1 or homologs of any of the several human genes known to be implicated in HCC, we did observe an increase in b-catenin protein expression. We plan to use mRNA microarray profiling of SBinduced HCC to clarify whether our system models one or more of the non-CTNNB1 subclasses of HCC. Regardless, based on our comparison of CIS genes to gene copy number and expression changes in human HCC, it appears that homologs of three of the genes on our list-UBE2H, QKI and MAP2K4-are strong candidates for driving HCC. Moreover, homologs of several of the other CIS genesincluding MET, EGFR and HIF1A-have been studied specifically in the context of human HCC and are likely to play a role in the development of this disease. Taken together, this indicates that the SB screen yields a high fraction of relevant events in human HCC.
These studies, combined with others showing that conditional transposon-based insertional mutagenesis can be used to model solid tumors in other organ sites such as brain and gastrointestinal tract (data not shown), define a powerful new method for dissecting the cancer genome and for developing better treatments for cancer. Future research directions include using this technology for further validation of both the HCC-and metastasis-associated genes identified here.
METHODS
Generation of transgenic animals. Alb-Cre transgenic animals were purchased from Jackson Laboratory 16 . They were initially bred with T2/onc homozygotes to obtain doubly transgenic animals carrying both Alb-Cre and T2/onc. The T2/onc transgenic line with the donor concatemer on chromosome 15, generated as previously described 8 , was used in this study. Simultaneously, transgenic animals heterozygous for Rosa26-lsl-SB11 and p53-lsl-R270H (purchased from NCI, Frederick Mouse Repository) were interbred to obtain doubly transgenic animals. The two doubly transgenic lines were finally interbred to generate the required triple (Alb-Cre/ T2/onc/Rosa26-lsl-SB11), quadruple (Alb-Cre/T2/onc/Rosa26-lsl-SB11/p53-lsl-R270H) and control animals of various transgene combinations. The genetic background of these animals was mixed, allowing for a diverse genetic population analysis.
PCR genotyping. Identification of the various genotypes from both adult transgenic animal and pups was performed as follows. First, genomic DNA was isolated from tail clippings using standard proteinase-K treatment, phenolchloroform extraction and ethanol precipitation. Genomic DNA was then dissolved in sterile TE (10 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8)) and quantified using a Nanodrop spectrophotometer. PCR genotyping was performed using 100 ng of diluted genomic DNA as template. PCR primers used for Alb-Cre were forward 5¢-CACACTGAAATGCTCAAATGGGAGA-3¢ and reverse 5¢-GGCAAATTTTGGTGTACGGTCAGTA-3¢ (amplicon 456 bp); T2/ onc forward 5¢-CGCTTCTCGCTTCTGTTCGC-3¢ and reverse 5¢-CCACCCC CAGCATTCTAGTT-3¢ (amplicon 264 bp); Rosa26-lsl-SB11 were Rosa26 wildtype forward 5¢-CTGTTTTGGAGGCAGGAA-3¢, Rosa26 wild-type reverse 5¢-CCCCAGATGACTACCTATCCTCCC-3¢, SB reverse 5¢-CTAAAAGGCCTATCA CAAAC-3¢ (Rosa26 wild-type and Rosa26-lsl-SB11 amplicons are 420 bp and 266 bp, respectively); p53-lsl-R270H were p53 wild-type forward 5¢-TTACA CATCCAGCCTCTGTGG-3¢, p53 wild-type reverse 5¢-CTTGGAGACATAGC CACACTG-3¢, p53-lsl-R270H conditional forward 5¢-AGCTAGCCACCA TGGCTTGAGTAAGTCTGCA-3¢ (p53 wild-type and p53-lsl-R270H conditional allele amplicons are 170 bp and 270 bp, respectively); glyceraldehyde-3-phosphate dehydrogenase (Gapdh) were forward 5¢-GGAGCCAAACGGGT CATCATCTC-3¢ and reverse 5¢-GAGGGGCCATCCACAGTCTTCT-3¢ (amplicon 233 bp). PCR conditions for Taq polymerase (CLP) were used according to the manufacturer's instructions with an initial denaturing step of 94 1C for 5 min; 35 cycles of denaturing at 94 1C for 1 min, annealing at 55 1C for 1 min and extension at 72 1C for 1 min; followed by a final extension at 72 1C for 7 min. PCR products were separated on a 2% agarose gel and genotype determined by the absence or presence of expected amplicons.
Liver tumor analysis. The whole liver was carefully removed from the euthanized animal, washed and placed in cold PBS. The number of surface liver tumor nodules was counted for all liver lobes. All reasonably sized tumor nodules (42 mm in diameter) were carefully removed from the liver lobes using fine forceps and placed in fresh cold PBS. These separated nodules were then halved using a sterile razor blade and split into samples for DNA and RNA extraction. Tissue samples for RNA were stored at -80 1C in RNAlater (Sigma) to prevent RNase contamination and degradation. Histological sections were taken only for larger tumor nodules (42 mm in diameter), in addition to the samples for DNA and RNA extraction. DNA extraction was done as previously described in the PCR genotyping section. Extraction of RNA was done using the Trizol reagent (Invitrogen) using protocols described by the manufacturer. Formalin fixed-paraffin embedded sections from various tissues were sectioned at 5 mm using a standard microtome (Leica), mounted and heat-fixed onto glass slides. Tissue section slides were either processed and stained with hematoxylin-eosin (HE) using standard protocols, or used for immunohistochemistry as described in the next section.
Immunohistochemistry. Formalin-fixed, paraffin-embedded sections from various tissues were sectioned at 5 mm, mounted and heat-fixed onto glass slides to be used for immunohistochemical analyses. Briefly, the glass section slides were dewaxed and rehydrated through a gradual decrease in ethanol concentration. The antigen epitopes on the tissue sections were then unmasked using a commercially available unmasking solution (Vector Laboratories) according to the manufacturer's instructions. The tissue section slides were then treated with 3% hydrogen peroxide to remove any endogenous peroxidases. Blocking was performed at 4 1C using a M.O.M. mouse immunoglobulin-blocking reagent (Vector Laboratories) in a humidified chamber for several hours. The sections were then incubated overnight at 4 1C in a humidified chamber using various primary antibodies: SB transposase (1:100) (R&D Systems), Alb (1:200) (Abcam), Afp (1:100) (GeneTex), Ki67 (1:200) (Novocastra), b-catenin (1:500) (BD) and Fah (1:250) (AbboMax). After primary incubation, sections were washed thoroughly in PBS before incubating with horseradish peroxidase-secondary antibody raised against the primary antibody initially used. After thorough washes with PBS, the sections were treated with freshly prepared DAB substrate (Vector Laboratories) and allowed to develop adequate signal before stopping the reaction in water. For EGFR immunohistochemistry, EGFr Kit (Clone 31G7) (Zymed Laboratories, Invitrogen) was used according to the manufacturer's instructions, except for the following modification. An additional overnight blocking step using the M.O.M. mouse immunoglobulin-blocking reagent was incorporated after proteinase K treatment to reduce background staining. Finally, sections were then lightly counter-stained with hematoxylin, dehydrated through gradual increase in ethanol concentration, cleared in Citrosol and mounted in Permount (Fisher).
Pyrosequencing. Protocol for amplicon sequencing using the GS20 Flex pyrosequencing machine was as previously described by Roche. Briefly, 100 ng of genomic DNA isolated from individual tumors was digested with either BfaI or NlaIII, for left or right transposon IR/DR, respectively. A small volume of this enzyme digest was used for splinkerette linker attachment using the appropriate linker. To make the BfaI linker, the following oligonucleotide sequences were annealed together using standard protocols, top strand 5¢-GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC-3¢ and bottom strand 5¢-TAGTCCCTTAAGCGGAG-3¢. As for the NlaIII linker, the following oligonucleotide sequences were annealed together using standard protocols, top strand 5¢-GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG-3¢ and bottom strand 5¢-GTCCCTTAAGCGGAGCC-3¢. Linker ligations were performed overnight at 16 1C using T4 DNA ligase (New England Biolabs). The ligation reaction was cleaned using MinElute 96-well plates (Qiagen) in a vacuum manifold and resuspended in 40 ml of sterile double-distilled water (DDW). This resuspended solution was then digested with either BamHI or XhoI, for left or right transposon IR/DR, respectively. A small volume was then used for primary PCR using the following primers. Left IR/DR primer (BfaI), 5¢-CTGGAATTTTCCAAGCTGTTTAAAGGCACAGTCAAC-3¢; right IR/DR primer (NlaIII), 5¢-GCTTGTGGAAGGCTACTCGAAATGTTTGACCC-3¢ and common splinkerette primer was used for both IR/DRs, 5¢-GTAATACGACTC ACTATAGGGC-3¢. PCR conditions for Taq polymerase (CLP) were used according to the manufacturer's instructions of an initial denaturing step of 94 1C for 5 min; 30 cycles of denaturing at 94 1C for 30 s, annealing at 60 1C for 30 s and extension at 72 1C for 1.5 min; followed by a final extension at 72 1C for 5 min. One microliter of the diluted first PCR product sample (1:75) was used as a template for the secondary PCR under the following conditions. Nested versions of the above primers carrying the required fusion sequences for GS20 Flex pyrosequencing (Fusion A and Fusion B), as well as a unique 10-bp barcode recognition sequence for each tumor sample. Primers were designed as such that the nested transposon primer have the Fusion A and barcode attached (Fusion A -barcode -nested primer) and the nested linker primer has the Fusion B sequence attached (linker nested -Fusion B). PCR conditions for Taq polymerase (Roche FastStart High Fidelity) were used according to the manufacturer's instructions of an initial denaturing step of 94 1C for 5 min; 35 cycles of denaturing at 94 1C for 30 s, annealing at 60 1C for 30 s and extension at 72 1C for 1.5 min; followed by a final extension at 72 1C for 5 min. After the secondary PCR, the reaction was purified using MinElute 96-well plates in a vacuum manifold and resuspended in 30 ml of sterile TE. The amount of DNA in each PCR sample was quantified using the QuantIT picogreen kit (Invitrogen) and the samples were diluted to a final concentration of 2 Â 10 5 molecules/ml for pyrosequencing. Egfr PCR genotyping. PCR genotyping was used to confirm the presence of the T2/onc transposon insertion in intron 24 of the Egfr gene. Briefly, genomic DNA was isolated from individual tumor nodules using protocols already described in the PCR genotyping section. PCR genotyping was performed using 100 ng of diluted genomic DNA as template. PCR primers used for Egfr intron 24 were forward, 5¢-TACATGGTCAAAATCTCTCCAATAGGTC-3¢ and reverse, 5¢-ATTAGAAAGGGCAACGAAGCTTGC-3¢, with an expected amplicon of 713 bp. A third primer specific for the IR/DR-R (T/JB3) of the T2/onc transposon vector was also included, 5¢-AGGGAATTTTTACTAGGATTAA ATGTCAGG-3¢. PCR conditions were as described previously in the PCR genotyping section. The amplicon sizes varied depending on the position of the T2/onc transposon vector insertion site.
